Form 8-K - Current report:
SEC Accession No. 0001193125-22-055741
Filing Date
2022-02-28
Accepted
2022-02-28 07:08:04
Documents
15
Period of Report
2022-02-28
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d211747d8k.htm   iXBRL 8-K 28622
2 EX-99.1 d211747dex991.htm EX-99.1 6646
7 GRAPHIC g211747g0228005700734.jpg GRAPHIC 2156
  Complete submission text file 0001193125-22-055741.txt   211829

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20220228.xsd EX-101.SCH 4504
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE roiv-20220228_def.xml EX-101.DEF 14700
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20220228_lab.xml EX-101.LAB 24853
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20220228_pre.xml EX-101.PRE 15792
9 EXTRACTED XBRL INSTANCE DOCUMENT d211747d8k_htm.xml XML 6177
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 22683888
SIC: 2834 Pharmaceutical Preparations